Navigation Links
12-Month ATLANTA Trial Data Show Sustained Benefit of Catania(TM) Stent in Treatment of De Novo Coronary Lesions
Date:10/13/2008

struts) by investigators using Optimal Coherence Tomography at baseline and again at 6-month follow-up in a subset of 15 randomly selected patients revealed complete endothelialization and 99.5 percent stent strut coverage.

"Every clinician is aware of the questions and issues surrounding drug-eluting stents and the increased risk of late and very late stent thrombosis, malapposition, inflammatory or hypersensitivity reactions, as well as the economic impact of maintaining long-term dual antiplatelet therapy," said Corrado Tamburino, MD, PhD, FESC, FSCAI, FSICI-GISE, Professor of Cardiology and Chief of the Cardiovascular Department, Ferrarotto Hospital, Catania, Italy, and lead investigator in the ATLANTA Trial. "The 12-month ATLANTA data indicate that the CATANIA(TM) stent with Polyzene(R)-F is truly a new and promising class of stent. Further, the CATANIA(TM) stent may offer an improved safety profile as evidenced by the fact that there were no deaths, myocardial infarctions, or stent thrombosis in a significantly complex patient population. Economically, this stent has merit, because it does away with the costs associated with long-term dual antiplatelet therapy."

The rapid-exchange, cobalt-chromium CATANIA(TM) stent carries a CE Mark and is currently available for sale outside of the United States in 60 sizes, in lengths from 8-38mm and in diameters from 2.0-4.0mm. "The CATANIA(TM) stent represents the next evolution in angioplasty treatment," said Thomas A. Gordy, President and Chief Executive Officer, CeloNova Biosciences, Inc. "Physicians, health care systems, and insurance programs need breakthroughs, not devices that are marginally better than what already exists. Marginal improvements advance competition; we need to be advancing medicine first."

The CATANIA(TM) stent surface has a thin (35-40 nanometers) surface treatment of highly lubricious Polyzene(R)-F, a synthesized, inorganic, biocompatible polymer that is anti-thrombotic, anti-
'/>"/>

SOURCE CeloNova BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Long-Term 12-Month Safety Data Presented on ADHD Patch DAYTRANA(TM) (methylphenidate transdermal system)
2. Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
3. XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
4. Boston Scientific to Release Broad Range of Clinical Trial Data on the Performance of TAXUS(R) Coronary Stent Systems at TCT 2008
5. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
6. Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent
7. Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
8. Texas Cardiac Arrhythmia Institute at St. Davids Medical Center Selected to Conduct Clinical Trial for Device to Treat Atrial Fibrillation
9. Study Published in Journal of Clinical Psychiatry Showed Once-Daily VYVANSE(R) (lisdexamfetamine dimesylate) Significantly Improved ADHD Symptoms in One of the Largest Controlled Stimulant Trials in Adults with ADHD
10. Peregrine Pharmaceuticals Completes Patient Enrollment in First Stage of Its Second Bavituximab Phase II Breast Cancer Trial
11. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... DUBLIN , Aug. 28, 2015 ... announced the addition of the "Investigation Report on ... Tobramycin is a traditional antibiotic whose eye ... for the treatment of potential infection or inflammation caused ... China are able to produce tobramycin, ...
(Date:8/28/2015)... -- Research and Markets ( ... "Investigation Report on China,s Quetiapine Market, 2010-2019" ... by AstraZeneca plc, quetiapine (under the trade name ... treatment of schizophrenia. Approved by CFDA to treat ... Catalogue of Drugs for the Basic National Medical ...
(Date:8/28/2015)... Research and Markets ( http://www.researchandmarkets.com/research/sqh7xc/investigation ) ... on China,s Ranibizumab Market, 2012-2019" report to their ... by CFDA to treat wet age- related macular degeneration ... Novartis, is available in the Chinese market. However, in ... the treatment of wet AMD in China ...
Breaking Medicine Technology:Investigation Report on China's Tobramycin Market, 2015-2019 2China Quetiapine Market Investigation Report 2010-2019 2Investigation Report on China's Ranibizumab Market, 2012-2019 2
(Date:8/29/2015)... ... ... Brands like Toppik , Eau Thermale Avene and Bliss are now available ... $49.00 was required to qualify for free standard shipping,” said Jennifer Ramirez, the public ... regardless of the item’s selling price.” , With competitive pricing in the e-commerce market ...
(Date:8/29/2015)... ... August 29, 2015 , ... ProDrop Particles includes over 40 particle backdrops ... seconds of unique footage that users can shrink and stretch in the Final Cut ... Users can customize color, brightness, scale, speed, range, and flare attributes with intuitive controls ...
(Date:8/29/2015)... ... August 29, 2015 , ... Hamstring strain have ... soft tissue manipulation. Platelet rich plasma injections also have mixed results. Building ... treatment outcomes. This localized treatment seems to address the symptoms and does ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... freely market and sell Arterosil and Arterosil HP, and that all claims and ... sued Vascular Health Sciences, LLC (VHS) in the United States District Court for ...
(Date:8/28/2015)... Madre, CA (PRWEB) , ... August 28, 2015 ... ... solutions to wound center management, Decatur County Memorial Hospital recently transitioned management companies ... model of Wound Center Management for their outpatient wound center. , Transitioning ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Discounts Shipping on Select Brands 2Health News:FCPX Effects Developer, Pixel Film Studios, Releases ProDrop Particles. 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 2Health News:NEW APPROACH for Treatment of Recurrent Hamstring Strains and Hamstring Tendinosis is Available for the First Time in NYC 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 2Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 3Health News:Decatur County Memorial Hospital Transitions Wound Center Management To Wound Care Advantage and the Luvo Operating System 4
... 21 (HealthDay News) -- Physically unfit men who do heavy ... a new study says. It also found that income ... socioeconomic levels are more likely to have lifestyle risk factors ... in lower and higher socioeconomic levels. Thirty percent of the ...
... Ill. -- Many premature infants suffer a life-threatening ... a Loyola University Medical Center study has identified a ... blood type who develop NEC are nearly three times ... other blood types., The finding suggests that a simple ...
... A team of University of Missouri researchers have found that ... the severity of the disease Spinal Muscular Atrophy (SMA) ... "When we introduced synthetic RNA into mice that carry ... lowered," said Chris Lorson, researcher at the Bond Life Sciences ...
... HealthDay Reporter , MONDAY, Nov. 21 (HealthDay News) -- ... Monday issued new recommendations on breast cancer screening, and ... a U.S. governmental panel. As the U.S. Preventive ... government-appointed Canadian panel of experts is also suggesting that ...
... (HealthDay News) -- ,Death rates for U.S. patients with throat and ... The finding comes from an analysis of National Center for ... 25 to 64, in 26 states. The researchers also ... throat (pharynx) cancers were among black patients with at least 12 ...
... , MONDAY, Nov. 21 (HealthDay News) -- Young ... death decades later, according to a new study. High ... disease and stroke but most of the evidence supporting this ... For this investigation of the long-term impact of elevated ...
Cached Medicine News:Health News:Life-threatening condition in preemies linked to blood type 2Health News:New Canadian Guidelines Also Support No Routine Mammograms Until 50 2Health News:New Canadian Guidelines Also Support No Routine Mammograms Until 50 3Health News:Fewer Dying in U.S. From Throat, Mouth Cancer, Study Finds 2Health News:Hypertension in Young Adulthood May Mean Trouble Later On 2
... Dissectron ultrasonic aspirator, ... ultrasonic surgical aspirator for ... of tissue available only ... Gathers in a very ...
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 7.0 mm and length 7.5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 8.0 mm and length 5 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Deflected large type, opening width 8.0 mm and length 5 mm....
Medicine Products: